The purpose of this regulation is:
- To facilitate the development of, and access to, drugs.
- To ensure that the drugs are good quality and in a form suitable for the child and his/her age.
- To supply the clinical information necessary for their efficacy and safety without subjecting the child to unethical trials.
In partnership with clinicians Advicenne is focusing on the treatment of neglected/orphan diseases of the central nervous system and certain renal disorders. These two treatment fields are cruelly short of drugs adapted to children.
ADVICENNE is, and will remain, above all and throughout its development a company committed to patients, more especially children who suffer from rare or neglected diseases, putting scientific innovation and medical excellence at the service of pediatrics.